Dimensional Fund Advisors
HTGM

Dimensional Fund Advisors’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Dimensional Fund Advisors’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-76
Closed -$23K – 3446
2019
Q2 		$23K Hold
76
– – ﹤0.01% 3449
2019
Q1 		$34K Hold
76
– – ﹤0.01% 3422
2018
Q4 		$35K Hold
76
– – ﹤0.01% 3411
2018
Q3 		$70K Buy
+76
New +$50.2K ﹤0.01% 3378

Other funds holding HTGM

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Dimensional Fund Advisors's HTGM Position: Q3 2019 in Review

Dimensional Fund Advisors sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q3 2019, closing a stake of 76 shares — an estimated $23K sold.

Dimensional Fund Advisors first reported a position in HTGM in Q3 2018 and held it in 4 quarters. The position peaked at $70K in Q3 2018. 44 funds tracked by Wall St. Rank hold HTGM as of Q3 2019.

  • Dimensional Fund Advisors reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Dimensional Fund Advisors sold 76 HTG Molecular Diagnostics, Inc. Common Stock shares in Q3 2019, an estimated $23K.
  • Dimensional Fund Advisors first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2018 and held it in 4 quarters.
  • Dimensional Fund Advisors's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $70K in Q3 2018.
  • 44 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q3 2019.

Based on Dimensional Fund Advisors's 13F filing for Q3 2019, filed 12 Nov 2019.